Fermion Oy Fermion Oy

X

Find the latest Drugs in Development and Pipeline Prospector News of Celsius Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Celsius Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
399 Binney Street Cambridge, MA 02139
Telephone
Telephone
857-776-7400

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

CEL383 is a potential first-in-class antibody directed towards Triggering Receptor Expressed on Myeloid Cells 1 that Celsius is advancing for the treatment of inflammatory bowel disease (IBD).


Lead Product(s): CEL383

Therapeutic Area: Gastroenterology Product Name: CEL383

Highest Development Status: Phase IProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CEL383, an anti-TREM1 antibody, a myeloid target with a central role in inflammatory bowel disease. TREM1 is the first of these targets, an amplifier of mucosal inflammation that resides at the intersection of the microbiome and the immune system.


Lead Product(s): CEL383

Therapeutic Area: Gastroenterology Product Name: CEL383

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Celsius Therapeutics will collaborate for the development of a systems pharmacology model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).


Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Applied BioMath

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 04, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of collaboration, Celsius will analyze hundreds of samples from defined CRC patient populations using its proprietary single-cell genomics platform and will work to identify and validate new drug targets during the three-year research period.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Partner/Sponsor/Collaborator: Servier

Deal Size: $700.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration December 21, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Celsius will partner with leading academic scientists to access patient tissue samples and apply its proprietary single-cell genomics platform and machine learning capabilities to discover new insights into inflammatory bowel disease (IBD).


Lead Product(s): Undisclosed

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Partner/Sponsor/Collaborator: University of Oxford

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 01, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY